1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Hikal Limited

Hikal Limited

202.85
INR
-8.15
(-3.86%)
-2.74EPS
27.28BMarket Cap
Nov 11Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
67.12
69.67
73.67
83.8
105.32
128.78
118.58
138.45
156.21
162.59
143.45
149.51
137.48
139.95
Basic EPS, GAAP
5.18
3.28
3.34
5.49
6.26
8.36
6.85
10.8
13.02
6.36
5.64
7.36
-3.96
-2.74
Free Cash Flow per Basic Share
8.35
4.35
10.28
3.36
2.66
4.64
10.29
5.79
1.66
1.03
-1.42
11.61
12.48
- -
Dividend per Share
0.7
0.39
0.8
1.28
1.04
1.33
1.93
1.2
2.2
1
1.2
1.2
1
- -
Book Value per Share
40.93
43.19
44.93
49.07
54.29
61.33
66.22
75.7
86.62
91.93
96.33
102.38
97.23
- -
Tangible Book Value per Share
40.93
43.19
44.88
48.94
53.82
60.66
65.34
74.87
85.78
91.1
95.51
101.74
96.76
- -
Basic Weighted Avg Shares
123
123
123
123
123
123
123
123
123
123
123
123
123
123
Sales/Revenue/Turnover
8,276
8,591
9,084
10,332
12,986
15,879
14,621
17,071
19,260
20,047
17,687
18,435
16,952
17,237
Operating Margin (%)
17.38
13.98
12.8
12.95
12.42
13.41
13.07
13.98
12.71
7.43
8.46
10.56
3.4
3.78
Depreciation Expense
550
642
673
691
856
929
825
852
957
1,090
1,176
1,344
1,638
1,671
Net Income, GAAP
639
404
412
677
772
1,031
844
1,331
1,605
784
696
908
-488
-338
Effective Tax Rate (%)
34.88
32.38
22.54
15.63
30.73
30.86
33.29
35.5
26.56
25.61
27.12
26.66
- -
- -
Profit Margin (%)
7.72
4.7
4.54
6.55
5.95
6.49
5.77
7.8
8.33
3.91
3.94
4.93
-2.88
-1.96
Working Capital
279
-170
892
1,365
1,299
2,275
1,784
2,218
1,951
2,775
2,100
2,059
2,052
- -
LT Debt
2,548
2,014
2,877
3,202
2,966
2,978
3,043
2,635
2,869
4,899
4,255
3,696
3,758
- -
Total Equity
5,047
5,325
5,540
6,050
6,694
7,562
8,165
9,334
10,680
11,335
11,877
12,623
11,988
- -
Return on Invested Capital (%)
6.36
3.94
3.7
5.75
8.82
10.57
8.11
10.13
10.85
6.06
5.6
7.04
- -
- -
Return on Capital (%)
9.88
7.25
6.84
9.18
8.68
9.99
8
10.23
10.94
6.01
5.58
7.15
- -
- -
Return on Common Equity (%)
13.38
7.79
7.58
11.69
12.12
14.46
10.74
15.22
16.04
7.12
6
7.41
-3.97
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
3,080
- -
LT Borrowings
- -
3,731
- -
LT Finance Leases
- -
27
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
123
123
123
Market Capitalization
27,977
18,131
27,280

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
8,841
- -
Cash, Cash Equivalents & STI
- -
136
- -
Accounts Receivable, Net
- -
4,416
- -
Inventories
- -
3,581
- -
Total Current Liabilities
- -
6,789
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
3,080
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.17%
5.32%
-5.03%
Free Cash Flow
-119.3%
-251.47%
7.55%
Net Income, GAAP
-1.36%
-33.02%
-153.74%
Sales/Revenue/Turnover
7.19%
0.27%
-8.04%
Total Cash Common Dividend
- -
- -
-16.89%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
4,038
4,508
4,389
5,500
18,435
2026
3,713
3,162
4,907
5,170
16,952
2027
3,998
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.41
1.48
1.39
4.07
7.36
2026
-1.82
-2.83
-0.48
1.17
-3.96
2027
-0.6
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
1.2
2026
- -
- -
- -
- -
1
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Sameer Jai Hiremath
Full Time Employees
3,133
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Great Eastern Chambers Mumbai MH India 400614
IPO Date
Jul 8, 1988
Website
hikal.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Hikal Limited, incorporated in 1988 and headquartered in Navi Mumbai, India, manufactures and supplies active pharmaceutical ingredients, intermediates, specialty chemicals, and crop protection products to global pharmaceutical, biotech, animal health, agrochemical, and specialty chemical companies; its core offerings span custom research, process development, contract development and manufacturing organization services, and commercial-scale production of generics APIs, new chemical entities, herbicides such as Diuron and 3,5-Dichloroaniline, insecticides including Temephos, Thiacloprid, and Clothianidin, fungicides like Prothioconazole and Trifloxystrobin, and biocides such as BIT, with operations across multiple US FDA-inspected facilities in India including sites in Panoli, Mahad, Taloja, Pune, and Bangalore serving markets in India, the United States, Europe, Canada, and Southeast Asia. The company operates through two primary segments—Pharmaceuticals, encompassing APIs, advanced intermediates, and high potency APIs for oncology and animal health, and Crop Protection, including active ingredients, custom synthesis, and contract manufacturing—with additional focus on biocides, personal care ingredients, and battery chemicals. In recent developments, Hikal has advanced its strategic transformation under Project Pinnacle by inaugurating a state-of-the-art high potency API laboratory and commissioning a new kilo lab to bolster early-stage development and niche oncology capabilities, completed development and validation of six animal health products under long-term innovator agreements with launches targeted for global markets, progressed toward commercializing 2-3 products in personal care and specialty chemicals, expanded its CDMO pipeline with 13-14 projects including two expected launches by FY26, intensified ESG initiatives, and broadened geographical reach and technology infrastructure to secure new customers amid ongoing remediation of regulatory challenges in its pharmaceutical segment.